While issues in science, regulation and reimbursement are still the focus of most stakeholders in personalized medicine, an increasing number of providers are integrating personalized medicine into the health care system despite obstacles. The 2nd Annual PMC/BIO Solutions Summit will convene representatives from industry, patient groups and payers as well as the increasing number of academic health centers and community health care systems that are already delivering personalized care to discuss those obstacles and, more importantly, identify the best practices for speeding the integration of personalized medicine into clinical care.
The event, co-hosted by PMC and the Biotechnology Industry Organization (BIO), will take place October 14, 2015 at the Renaissance Downtown Hotel in Washington, D.C. It features a distinguished line up of speakers.
Following introductory remarks, a panel including Centers for Medicare and Medicaid (CMS) Hospital and Ambulatory Group Acting Director Marc Hartstein will explore the issues involved in reviewing evidence for coverage of personalized medicine products and services. The session is designed to shed light on the kinds of data the personalized medicine community might focus on generating in order to convince payers that personalized medicine is worth paying for.
The event’s second session focuses on education. During this discussion, experts including David Flockhart of the Indiana Institute for Personalized Medicine will present strategies for ensuring that payers, providers, patients and other stakeholders stay up to date on the latest trends in the quickly evolving field.
The second session anticipates a luncheon keynote presentation that will feature a discussion between Illumina Senior Vice President & Chief Medical Officer Richard Klausner and AstraZeneca Vice President of Translational Sciences J. Carl Barrett. Klausner and Barrett will elevate the education discussion to the systems level, exploring the development of a framework for the efficient utilization of personalized medicine information throughout the health care ecosystem. Turna Ray, an editor at GenomeWeb, will moderate the discussion.
A third panel offers a look at how personalized medicine’s value can be demonstrated from a variety of perspectives. Bonnie J. Addario of the Bonnie J. Addario Lung Cancer Foundation will provide a patient voice, while representatives from an academic health center, a diagnostics company and Aetna will round out the discussion. The conversation will reveal arguments with which stakeholders can prove that personalized medicine is a worthwhile effort.
The event’s final panel will examine the infrastructure supporting personalized medicine. During this discussion, experts including Oracle Global Vice President of Health Sciences Jonathan Sheldon will explain the challenges involved in generating and managing the data required to deliver personalized care, as well as the options for overcoming these challenges.
At the conclusion of the final panel, representatives from PMC and BIO will summarize the solutions that were uncovered and provide an overview of next steps.
We look forward to seeing you at the event.
Personalized Medicine Coalition